Venrock Healthcare Capital Partners

Portfolio Co Investors 2026 for Venrock Healthcare Capital Partners: investors, rounds, and co-investor patterns from StartupFundraising.com research.

Venrock Healthcare Capital Partners accounts for 18 tracked companies with verified cap-table data, 18 of which disclose round sizes totalling $4.2B. The median disclosed raise is $175M, and the largest is Mirador Therapeutics at $650M, ahead of Spyre Therapeutics ($644M) and RayzeBio ($418M).

The names that recur most often on these co-invested cap tables are Venrock Healthcare Capital Partners (18 companies), Fairmount (7 companies), OrbiMed (5 companies), TCGX (4 companies), Cormorant Asset Management (4 companies), Vivo Capital (4 companies). By latest disclosed round, the market skews Series A (5), Series B (4), Series D (3), Series C (3).

Best funded Venrock Healthcare Capital Partners companies

  1. Mirador Therapeutics — $650M (latest: Series B)
  2. Spyre Therapeutics — $644M (latest: Growth)
  3. RayzeBio — $418M (latest: Series D)
  4. Candid Therapeutics — $370M (latest: Series A)
  5. CVRx — $340M
  6. Lycia Therapeutics — $232M (latest: Series D)
  7. ADARx Pharmaceuticals — $200M (latest: Series C)
  8. Timberlyne Therapeutics — $180M (latest: Series A)
  9. Korsana Biosciences — $175M (latest: Series A)
  10. Celcuity — $175M (latest: Series B)
  11. Apogee Therapeutics — $169M (latest: Series B)
  12. Tricida — $153M (latest: Series D)
  13. Jade Biosciences — $125M
  14. Dianthus Therapeutics — $100M (latest: Series A)
  15. Olema Oncology — $85M (latest: Series C)

Venrock Healthcare Capital Partners — related firms and companies (56)

Venrock Healthcare Capital Partners alternatives · All research reports